The first scenario exploring how global costs would change with universal access to supervised radical cure following G6PD testing highlights that healthcare provider costs could nearly double while household costs could fall by almost a half, leading to cost savings of US$93.6 million and the prevention of 6.1 million malaria cases. This evidence concerns the gene G6PD and malaria.